Kenneth J. Conway Joins Ciphergen Board of Directors
April 18 2006 - 10:00AM
PR Newswire (US)
FREMONT, Calif., April 18 /PRNewswire-FirstCall/ -- Ciphergen
Biosystems, Inc. (NASDAQ:CIPH) announced today that Kenneth J.
Conway, a senior executive in clinical diagnostics and
pharmaceuticals, has joined Ciphergen's Board of Directors. Gail S.
Page, President and CEO of Ciphergen, stated, "We are excited about
our entry into clinical diagnostics and have taken major
initiatives to accomplish this effectively. Ken's experience and
accomplishments, particularly in predictive medicine, will add an
important perspective to our Board and help us achieve our goals."
Mr. Conway has been an innovator and visionary leader of both
start-up and established businesses in his 35 years of working in
clinical diagnostics and pharmaceuticals. Ken began his career at
Corning, Inc., followed by a successful career at Chiron
Diagnostics where he served as President of the U.S. Immuno group
and as a member of the Office of the President. Mr. Conway was
responsible for strategic development, operations and
commercialization prior to the acquisition of Chiron Diagnostics by
Bayer Healthcare. Mr. Conway also founded Millennium Predictive
Medicine and Vitivity Inc., both companies focused in the
predictive medicine arena. Mr. Conway holds a B.S. from Rutgers
University and attended the Executive Program at Dartmouth
College's Dartmouth Institute, Tuck School of Business
Administration. Ken Conway commented, "I am looking forward to
working with Ciphergen as we embark into the oncology market with
Quest Diagnostics. Our objective is to improve patient outcomes by
utilizing the knowledge and new decision points based upon our
proprietary assays." About Ciphergen Ciphergen is dedicated to the
discovery and commercialization of protein molecular diagnostic
tests that improve patient care; and to providing collaborative
R&D services through its Biomarker Discovery Center(R)
laboratories for biomarker discovery for new diagnostic tests as
well as pharmacoproteomic services for improved drug toxicology,
efficacy and theranostic assays. Ciphergen develops, manufactures
and markets a family of ProteinChip(R) Systems and services for
clinical, research and process proteomics applications. ProteinChip
Systems enable protein discovery, validation, identification and
assay development to provide researchers with predictive,
multi-marker assay capabilities and a better understanding of
biological function at the protein level. Additional information
about Ciphergen can be found at http://www.ciphergen.com/. Safe
Harbor Statement Note Regarding Forward-Looking Statements: For
purposes of the Private Securities Litigation Reform Act of 1995
(the "Act"), Ciphergen disclaims any intent or obligation to update
these forward-looking statements, and claims the protection of the
Safe Harbor for forward-looking statements contained in the Act.
Examples of such forward-looking statements include statements
regarding the translation of its biomarker discovery programs into
diagnostic and theranostic assays that improve patient care. Actual
results may differ materially from those projected in such
forward-looking statements due to various factors, including
Ciphergen's ability to successfully discover, validate and assay
biomarkers that have diagnostic and/or theranostic utility, and our
ability to protect and promote our proprietary technologies.
Investors should consult Ciphergen's filings with the Securities
and Exchange Commission, including its Form 10-K dated March 17,
2006, for further information regarding these and other risks of
the Company's business. NOTE: Ciphergen, ProteinChip and Biomarker
Discovery Center are registered trademarks of Ciphergen Biosystems,
Inc. DATASOURCE: Ciphergen Biosystems, Inc. CONTACT: Sue
Carruthers, Investor Relations of Ciphergen Biosystems, Inc.,
+1-510-505-2297 Web site: http://www.ciphergen.com/
Copyright
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From May 2024 to Jun 2024
Ciphergen Biosystems (NASDAQ:CIPH)
Historical Stock Chart
From Jun 2023 to Jun 2024